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Abstract 
Hepatocyte growth factor (HGF) exerts prolif-
erative activities in thyrocytes upon binding to its
tyrosine  kinase  receptor  c-met  and  is  also
expressed in benign thyroid nodules as well as in
Hashimoto’s thyroiditis (HT).
The  simultaneous  expression  of  HGF/c-met
and three trasducers of tyrosine kinase receptors
(STAT3,  PI3K,  RHO)  in  both  the  nodular  and
extranodular tissues were studied by immuno-
histochemistry  in  50  benign  thyroid  nodules
(NGs), 25 of which associated with HT. The lig-
and/tyrosine kinase receptor pair HGF/c-met and
the  two  trasducers  PI3K  and  RHO  were
expressed in NGs, regardless of association with
HT, with a higher positive cases percentage in
HT-associated NGs compared to not HT-associat-
ed NGs (25/25 or 100% vs 7/25 or 28%; P<0.001).
HGF, PI3K and RHO expression was only stromal
(fibroblasts and endothelial cells), in all 32 reac-
tive NGs, while c-met localization was consistent-
ly  epithelial  (thyrocyes).  Immu  noreactions  for
HGF, c-met, PI3K and RHO were also apparent in
the extra-nodular tissue of HT specimens, where
HGF and PI3K were expressed not only in stromal
cells but also in thyrocyes along with the c-met.
Finally,  a  positive  correlation  was  observed
between the proportion of HGF, c-met, PI3K follic-
ular cells and the grade of lymphoid aggregates
in HT. In conclusion, HGF, c-met, PI3K are much
more frequently and highly expressed in HT com-
pared to NGs, and among all NGs in those pres-
ent in the context of HT. A paracrine effect of
HFG/c-met on nodule development, based on the
prevalent stromal expression, may be suggested
along with a major role of HGF/c-met and PI3K in
HT. Finally, the expression of such molecules in
HT may be regulated by lymphoid infiltrate. 
Introduction
Hashimoto’s thyroditis (HT) is the most preva-
lent autoimmune thyroid disease worldwide and
is characterized by variable clinical presentation
with  respect  to  proliferation  of  the  follicular
cells.
1,2 Thyrocyte  proliferation  may  be  very
intense in HT, thus leading to multiple nodular
lesions.
3-6 Increased  prevalence  of  HT  patients
with associated nodular goiter remains high in
moderately iodine-deficient areas such as south-
ern Italy.
5
Growth factors other than thyrotropin (TSH),
and cytokines favor the development of diffuse
and/or nodular goiter.
7-9 However, only few stud-
ies have evaluated the role of different growth
factors in the nodular variant of HT.
10,11
Recently, we reported the immunohistochem-
ical expression of the hepatocyte growth factor
(HGF)  in  HT-associated  nodular  goiter  speci-
mens and demonstrated that it was more fre-
quent and intense than what observed in non-HT
goiters.
4 Upon binding to its specific tyrosine-
kinase receptor (HGF-R or c-met), HGF exerts
mitogenic and anti-apoptotic activities in various
cell  types,  including  follicular  thyroid  cells.
12-14
Previous studies demonstrated that HGF and c-
met are expressed in hyperplastic nodules (but
non  in  normal  thyroid  tissue)  and  are  over-
expressed  in  papillary  thyroid  carcinomas
(PTC).
15-18
Similarly to activation of the other ligand/ tyro-
sine kinase receptors, activation of the HGF/c-
met signaling system recruits several intracellu-
lar  effectors,  including  phosphatidylinositol  3-
kinase (PI3K), Ras, adaptators GRB2 and SHC,
the docking protein Gab1, the member of the sig-
nal transducers and activators of transcription
family STAT3, bcatenin and RHO.
19-23 Such effec-
tors are ubiquitous, as they are expressed in all
human  tissues,  and  trigger  distinct  biological
events, i.e. growth, scattering and morphogene-
sis,  in  epithelial  cells.
21-29 Concerning  thyroid
oncology, expression of these ubiquitous effec-
tors (for instance, STAT3, PI3K) has been inves-
tigated mainly in malignant thyroid tumors aris-
ing from the follicular epithelium,
16,30-33 but rarely
together with expression of HGF/c-met.
16,30 The
few data available on the expression of such mol-
ecules  in  thyroid  nodules  of  HT  patients  are
mainly  focused  on  the  possible  association
between HT and thyroid cancer.
34 Larson and co-
workers reported that the PI3K pathway compo-
nents  p-Akt,  Akt1,  and  Akt2  were  highly
expressed in HT and HT-associated PTC, as well
as in non-PTC, but not in the normal follicular
epithelium. On this basis, they suggest that the
PI3K/Akt pathway activation might represent a
common  molecular  mechanism  between  the
chronic  autoimmune  inflammation  of  thyroid
and PTC.
34
Moreover,  two  recent  studies  related  PI3K
expression/activation  with  the  mechanisms  of
immunity  response.
35,36 It  is  well  known  that
autoimmune thyroide diseases is related with
the balance between T helper types 1 and 2 (Th1
and Th2) responses, by an involvement of Toll-
like receptors (TLR).
1,2,37 The subunit p85 of PI3K
participates, in this framework, in the ligation
with TLR controlling the Th1/Th2 balance for an
advantage of Th1 cytokines.
35Moreover, PI3K reg-
ulatory subunits p85 regulates the motility of T
and B lymphocytes.
36
Here we evaluate the immunohistochemical
expression  of  ligand/tyrosine  kinase  receptor
pair HGF/c-met and three trasducers of activated
tyrosine kinase receptors (STAT3, PI3K, RHO) in
benign thyroid nodules, half of which developed
in the context of background HT. To the best of
our knowledge, the expression of these mole-
cules has not been previously examined in HT.
Materials and Methods
Tissues collection
Fifty  surgical  thyroid  specimens  were
retrieved  from  the  files  of  our  Pathology
Department, while 5 normal thyroids (NT) were
harvested at autopsy. All specimens were 4% for-
malin-fixed and paraffin-embedded. The 50 sur-
gical specimens were from patients diagnosed
and  followed  up  at  our  Endocrine  Unit  and
included benign nodular goiters (NG), of which
25 were associated with HT. In such patients, the
diagnosis  of  HT  was  based  on  the  currently
accepted clinical, laboratory (circulating thyroid
antibodies)  and  ultrasonographic  criteria.  All
nodular lesions were studied along with the non-
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nodular tissue from the contralateral thyroid lobe
(Table 1). 
Hematoxylin-eosin-stained (H&E) sections of
each specimen were re-evaluated by the patholo-
gists in order to confirm the HT diagnosis, evalu-
ate  the  intra-glandular  inflammatory  lymphoid
aggregates and catalogue the lesions by cytologi-
cal  morphology.  HT  was  diagnosed  using
histopathologic criteria of Li Volsi.
38
The lymphoid aggregates were categorized as
previously reported.
4,11 Briefly, aggregates made
up of at least 150 lymphocytes and a variable
number  of  plasma  cells  per  high-power  field,
were  considered  as  lymphoid  aggregates  and
scored from 0 to 3 (0=no lymphoid aggregate or
at  most  one  single,  small  lymphoid  aggregate
without germinal center in each section; 1=occa-
sional, usually small lymphoid aggregates with
rare or absent germinal centers in each section;
2=several, usually mixed, small and large lym-
phoid aggregates with some germinal center in
each  section;  3=numerous,  large  lymphoid
aggregates  with  frequent  germinal  centers  in
each section).
Cellular morphology was classified according
to the nuclear and cytoplasm features at light
microscopy, as previously reported.
4,39 Based on
these morphological features, the thyrocytes of
each lesion were classified into three different
cellular types: i) dark nucleus and eosinophilic
cytoplasm (DN-EC); ii) dark nucleus and onco-
cytic cytoplasm (DN-OC or Hurtle cells); iii) clear
nucleus  and  eosinophilic  cytoplasm  (CN-EC)
(Table 1). 
Immunohistochemistry
The 55 blocks were cut into serial sections of
five-micrometers  each.  Immunohisto  chemistry
was performed, separately, using rabbit polyclon-
al  antibodies  against  HGF-ʱ (H-145,  working
dilution (w.d.) 1:100), c-met (p140 anti h-met,
w.d.  1:100)  and  STAT3  (h-190,  w.d.1:100),  all
three purchased from Santa Cruz Bio  technology,
Inc. (Santa Cruz, CA, USA); a mouse monoclonal
antibody against PI3K p85ʱ (B-9, w.d. 1:200),
purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA), and a rabbit monoclonal
antibody  against  RHO  (Y486,  w.d.1:100),  pur-
chased from Abcam plc., Cambridge, UK. Tissue
sections were deparaffinized in xylene and rehy-
drated in alcohol. Next, the endogenous biotin
was inactivated by the addition of a 0.05% (v/v)
solution  of  streptavidin  in  phosphate-buffered
saline (PBS), and the endogenous peroxidase
activity  was  quenched  by  adding  a  0.3%  (v/v)
solution  of  3%  H2O2/methanol  for  30  min.
Staining was obtained with the LSAB system (kit
from  Dako,  Carpinteria,  CA,  USA).  3,3’-
diaminobenzidine (DAB, Sigma) activated with
0.05% hydrogen peroxide was used to develop the
end  reactions.  Sections  were  counterstained
with  Mayer’s  hematoxylin,  dehydrated  and
mounted. 
Specificity  of  the  antibody  binding  was
assessed by omitting the primary antiserum or by
replacing  the  primary  antiserum  with  normal
rabbit or mouse serum. In each of these condi-
tions, no staining was evident. In addition, an
immunoabsorption test was performed to con-
firm the specific immunoreactivity of each anti-
body. Specimens of normal tissues of bladder and
liver were used as positive controls for HGF and
c-met  immunoreaction,  respectively.  Positive
controls for STAT3, PI3K and RHO immonoreac-
tion were performed by using specimens of lung,
breast  and  liver  carcinomas,  respectively.  The
evaluation of the results was based on: i) number
of positive cases; ii) number of reactive epithelial
and stromal cells per case, based on counting
1000 cells/case at 50X magnification; iii) subcel-
lular location of the staining: membrane, cyto-
plasm and nucleus; iv) staining grade using a
semiquantitave score system from 0 to 4+ (0,
absent; 1+, weak but distinct; 2+, moderate; 3+ ,
intense;  4+,  very  intense).  Histological  and
immunohistochemical  evaluations  were  done
twice and blindly by two pathologists (M.T., G.B.)
with  an  inter-observer  concordance  of  nearly
100%. Where minimal inter-observer discrepan-
cies were present, data were averaged.
Statistical analysis
Data were tested for normal distribution and
variance (mean ± SD) and analyzed by the two-
tailed Student’s t-test, ANOVA and ˇ
2 test with
Yates’ correction for continuity, when appropri-
ate. The association between two variables was
analyzed by the linear regression analysis. The
level of statistical significance was always set at
P<0.05. 
Results
Histopathology and cellular 
morphology 
All the 50 benign NGs showed the histological
features  of  colloid  nodules  characterized  by
either large or small colloid-filled follicles built by
cells with small flat or cubic shape. Instead, cellu-
lar hallmarks of these lesions were the epithelial
follicular cells with DN-EC features, even if in
most cases of HT-associated NGs, DN-OC cells
and seldom CN-EC cells too were observed (Table
1). The predominant cellular type in HT showed
features of DN-EC cells.  Intra-nodular lymphoid
aggregates were absent (grade 0) in all 50 NGs.
Extra-nodular  lymphoid  aggregates  were  the
main histological evidence of HT. These aggre-
gate were graded as 1 (10/25 or 40%), 2 (12/25 or
48%) or 3 (3/25 or 12%). As previously specified
into the Materials and Methods paragraph, the 25
HT specimens were from patients diagnosed at
our Endocrine Unit, and all of them have circulat-
ing anti-thyroid antibodies. 
Immunohistochemistry 
Illustrative immunohistochemistry for HGF, c-
met, PI3K and RHO is presented in Figure 1. No
expression of HGF, c-met, STAT3, PI3K and RHO
was detected in normal thyroid tissue, namely
the control normal thyroids and the contralateral
lobe  to  the  25  NGs  not  associated  with  HT.
Similarly,  no  immunostaining  for  STAT3  was
observed in all nodular lesions.
Expressions of HGF/ c-met/PI3K/RHO in
NGs
The  ligand/tyrosine  kinase  receptor  pair
HGF/c-met and the two trasducers PI3K and RHO
were expressed in NGs, regardless of association
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Table 1. Expression of HGF, c-met, PI3K and RHO on epithelial and stromal cells in a
series of 25 colloid nodular goiters (NGs) and of 25 nodular Hashimoto's thyroditis
(HT) examined along with the corresponding extra-nodular thyroid tissue. 
Thyroid lesions Positive  Reactive* Percentage of positive cells (mean ±SD)° 
cases cases cells*
HGF c-met PI3K RHO
Colloid nodular  7 (28%) Epithelial (DN-EC) 0 4±2 00
goiters (NGs, n = 25) stromal  9±2 0 7±3 8±3
NGs  associated  25 (100%) Epithelial (DN-EC) 0 4±2 00
with HT (n = 25) stromal  12±8 0 8 ± 4 7±3
Extra-nodular thyroid  25 (100%) Epithelial
tissue of HT (n = 25) DN-EC  58±20 19±5 25 ± 8 0
DN-OC  24±25 9±8 00
CN-EC  21±13 8±5 00
stromal  11±8 0 8±4 8±3
*Thyroid  lesions  were  catalogued  by  cytological  morphology  of  thyrocytes  based  on  nuclear  and  cytoplasm  features  at  light
microscopy,
4,39 as detailed in Material and Methods. Based on these morphological features, the cells of each lesion were catego-
rized as: i) dark nucleus and eosinophilic cytoplasm (DN-EC); ii) dark nucleus and oncocytic cytoplasm (DN-OC); iii) clear nucleus
and eosinophilic cytoplasm (CN-EC). °The count of the reactive epithelial and stromal cells was based on evaluation of 1000
cells/case, using a 50X magnification. Values pertaining to stromal cells are typed in italics.[page 120] [European Journal of Histochemistry 2010; 54:e24]
with HT. However, significant differences in the
distribution of immunoreactions could be detect-
ed by comparing the NGs arising in the context of
HT with the HT-unassociated NGs. The expres-
sion of HGF, c-met, PI3K and RHO was detected
more frequently in the former than in the latter
nodules (25/25 or 100% vs 7/25 or 28%; P<0.001)
(Table 1). However, there were no differences in
the localization of immunostaining between the
two types of lesions. Thus, in all 32 reactive NGs,
HGF, PI3K and RHO expressions were only stro-
mal (fibroblasts and endothelial cells) and cyto-
plasmic, while the localization of c-met was con-
sistently  epithelial  (thyrocyes),  both  membra-
nous and cytoplasmic. The percentage of reactive
cells and the intensity of their immunoreactivity
were  similar  in  both  types  of  NGs.  Thus,
immunoreaction  for  HGF,  PI3K  and  RHO  con-
cerned 5-10% of stromal cells, and intensity of
immunostaining was weak or moderate. In the
same 32 nodules, a weak c-met immunoreaction
was restricted to 3-8% of thyrocytes (Table 1).
The c-met reactive epithelial cells of all 32 nod-
ules showed the cytological features of DN-EC
cells.
Expressions of HGF/ c-met/ STAT3/PI3-
K/RHO in the non-nodular tissue of HT
Immunoreactions  for  HGF,  c-met,  PI3K  and
RHO were also observed in the non-nodular tis-
sue of HT specimens, but their expression dif-
fered from what observed in NGs (Table 1). 
Indeed, while stromal expression of HGF, PI3K
and  RHO  matched  the  corresponding  stromal
expression in NGs, the cytoplasm of thyrocytes
also  expressed  HGF  and  PI3K,  an  epithelial
immunoreactivity  that  was  absent  in  all  NGs.
HGF and c-met were detected in thyrocytes with
DN-EC, DN-OC and CN-EC features, while PI3K
was expressed by epithelial follicular cells with
the sole DN-EC features (10-35%) (Table 1 and
Figure  1).  Hence,  thyrocytes  with  DN-EC  fea-
tures expressed the three molecules (HGF, c-met
and PI3K), while both DN-OC and CN-EC thyro-
cytes expressed only HGF and its receptor c-met.
Among thyrocytes immunoreacting for both HGF
and c-met, the major proportion of HGF and c-
met +ve cells showed DN-EC features (HGF+ve
DN-EC cells: 58±20%, range 30 to 80%; c-met +ve
DN-EC cells: 19±5%, range 10 to 25%; P<0.001 vs
the  corresponding  percentages  of  DN-OC  and
CN-EC cells) (Table 1). Moreover, all HT lesions
showed an intense stromal immunostaining for
HGF (which concerned 5-40% of cells) as well as
PI3K and RHO (5-15% of cells) (Table 1). Finally,
the staining grade observed for the four proteins
in HT was higher than that observed in NGs,
because it was moderate to very intense as com-
pared with weak to moderate (data non shown).
Comparing  the  proportion  of  DN-EC  cells
expressing the HGF, c-met and PI3K with the
grade of lymphoid aggregates, a positive correla-
tion was observed for the three protein [HGF:
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Table 2. Expression of HGF, c-met, PI3K and RHO on epithelial and stromal cells in the
extra-nodular tissue of the 25 cases of Hashimoto's thyroditis (HT), split into two sub-
groups (A and B) according to the presence or absence of germinal centers in the lym-
phoid infiltrate*. 
HT (n=25) Positive  Reactive Percentage of positive cells (mean ±SD)
# 
cases cells°
HGF c-met PI3K RHO
Group  A
#1-10 epithelial
(Lymphoid  DN-EC  37±8 14±4 17±4 0
aggregate grade 1)  DN-OC  4±8 2±4 00
(n=10) CN-EC  14±12 5±4 00
stromal  15±11 0 9±4 8±3
Group B
#11-25 epithelial
(Lymphoid  DN-EC 71±11 22±2 30±5 0
aggregate grade  DN-OC 38±22 13±7 00
2 and 3) ( n=15) CN-EC 26±13 10±4 00
P<0.001 vs Group A
stromal 7±5 0 8±3 7±2
P<0.025 vs Group A
*Lymphoid aggregates were scored from 0 to 3 (0=no lymphoid aggregate; 1=occasional lymphoid aggregates with rare or absent
germinal centers in each section; 2=several lymphoid aggregates with some germinal center; 3=numerous lymphoid aggregates with
frequent germinal centers), as detailed in Material and Methods. °Thyroid follicular cells were categorized as: i) dark nucleus and
eosinophilic cytoplasm (DN-EC); ii) dark nucleus and oncocytic cytoplasm (DN-OC); iii) clear nucleus and eosinophilic cytoplasm
(CN-EC), based on nuclear and cytoplasm features at light microscopy,
4,39 as detailed in Material and Methods. #The count of the
reactive epithelial and stromal cells was based on evaluation of 1000 cells/case, using a 50X magnification. Values pertaining to stro-
mal cells are typed in italics.
Figure 1. HGF, c-met, PI3K and RHO immunostaining in specimens of Hashimoto’s thy-
roditis (HT) and nodular goiters (NGs). Panel A: very intense HGF immunoreaction in a
sample of HT with lymphoid aggregates defined as grade 2. The HGF immunostaining is
located on the cytoplasm of thyrocytes (brown deposits) showing morphological charac-
teristics of DN-EC cells. Note the absence of HGF reactivity in the lymphocytes (original
magnification: X 150, reference bar = 133 mm). Panel B: intense c-met immunostaining
in a sample of HT with grade 2 lymphoid aggregates. The c-met reaction is observed on
the membrane and cytoplasm (brown deposits) of follicular DN-EC cells. No c-met reac-
tivity is detected in lymphocytes (original magnification: X 150, reference bar = 133 mm).
Panel C: moderate PI3K immunoreaction in a sample of HT with grade 2 lymphoid
aggregates. The immunoreaction is located in the cytoplasm of epithelial DN-EC cells
(brown deposits). Note the absence of PI3K reactivity in lymphocytes (original magnifi-
cation: X 130, reference bar = 153 mm). Panel D: moderate RHO immunoreaction in a
sample of NG not associated with HT. The RHO immunostaining is located on the cyto-
plasm of stromal cells (original magnification: X 130, reference bar = 153 mm).[European Journal of Histochemistry 2010; 54:e24] [page 121]
r=0.96,  P=0.17;  c-met:  r=0.91,  P=0.22;  PI3K:
r=0.94, P=0.27] (Figure 2). Moreover, by split-
ting the HT cases into two subgroups, according
to the presence or absence of germinal centers in
the  lymphocytic  infiltrate  (Table  2),  we  found
that the expression of c-met, PI3K and especially
HGF  in  epithelial  cells  was  much  more  pro-
nounced in the 15 cases with presence of germi-
nal centers (lymphocytic infiltrate grade 2 and 3),
as compared to the 10 cases with lymphocytic
infiltrate grade 1, in which the lymphoid aggre-
gates were occasional with rare or absent germi-
nal  centers  (P<0.001).  This  observation  rein-
forces the hypothesis that the expression of such
molecules in HT may be regulated by lymphoid
infiltrate.
Discussion
True nodular lesions frequently arise in the
context of HT, as consequence of a hyperplastic
follicular growth, which leads to an increase in
number and size of follicles. Several growth fac-
tors and cytokines are known to cooperate with
TSH in thyroid nodular growth, but few data are
available on their expression in nodular lesions
associated with HT.
10,11
In the present study, we report that the expres-
sion of the HGF/c-met system is associated with
that of the tyrosine kinase receptors trasducers
PI3K and RHO in both NGs and HT lesions, while
the normal thyroids do not express any. These
findings are in line with the known ability of HGF
to induce cellular growth, as well as with our pre-
vious reports in which we observed that HGF and
its receptor c-met are expressed in goitrous sam-
ples as well as in thyroid tissues with HT, but
undetectable  in  normal  thyroid  tissue.
4,15 Our
present study offers some new knowledge. 
First, we demonstrated the expression of the
tyrosine kinase receptors trasducers PI3K and
RHO in both HNs and HT lesions expressing the
HGF/cmet system, but we detected a more fre-
quent expression of HGF, c-met, PI3K and RHO in
the NGs associated with HT, either with scarce
lymphoid aggregates or with germinal centers, as
compared to non HT-associated NGs.
Another major result of our study is the differ-
ent localization of HGF and PI3K expressions in
NGs and HT, even when occurring in the same
thyroid gland. In the NGs, approximately 10% of
stromal cells expressed HGF, thus providing the
ligand for a paracrine interaction with the c-met
expressed on a limited number of epithelial cells.
However,  this  possible  interaction  was  not
accompanied by the epithelial expression of any
of the three trasducers investigated (STAT3, PI3K
and RHO). In fact, both PI3K and RHO expres-
sion was restricted to approximately 8% of the
stromal cells of NGs regardless of coexisting HT.
Therefore, the cellular localization of such mole-
cules  seems  to  be  independent  from  the  HT
lesion  associated  with  the  nodular  goiter.
Further, the expression of PI3K and RHO in stro-
mal cells appears to be independent from activa-
tion of the HGF/c-met signaling in this cellular
type, since there was no stromal expression of c-
met.  In  HT,  HGF  and  PI3K  immunoreactions
involved both stromal and epithelial cells, raising
the  possibility  of  c-met  activation  through  an
autocrine loop with subsequent involvement of
PI3K.  
The characterization of the follicular epithelial
cells of HT based on the nuclear and cytoplasmic
features allowed us to identify the follicular cells
with DN-EC features as the cellular type specifi-
cally involved in the epithelial pathway of HGF, c-
met and PI3K. Indeed, the epithelial co-expres-
sion of HGF, c-met and PI3K was observed only in
such cells, while the other reactive epithelial cel-
lular  types  expressed  only  the  ligand  and  the
receptor.
These evidences suggest that the HGF/c-met
system may play a role in the development of
nodular  goiter,  and  more  specifically  in  the
goitrous growth of HT. Moreover, these data sug-
gest that HGF acts as a goitrous growth factor in
a paracrine fashion in HT-associated or not HT-
associated  NGs,  but  both  in  a  paracrine  and
autocrine fashion in HT.  The expression of the
three  molecules  (c-met,  PI3K  and  especially
HGF) is much more pronounced in nodules asso-
ciated with diffuse HT, proved by the presence of
germinal centers, rather than in HT with scarce
lymphoid  aggregates.  In  those  latter,  however,
the expression of the investigated molecules is
significantly higher with respect to non HT-NGs. 
Finally,  the  positive  correlation  we  found
between the immunoistochemical expression of
HGF, c-met and PI3K in DN-EC cells and the lym-
phoid aggregates lead us to postulate that HGF, c-
met and PI3K signals may have a role also in the
mechanism of thyroid autoimmunity, as support-
ed by two recent studies relating PI3K expres-
sion/activation  with  the  mechanisms  of  the
immunity response.
35,36 In this way, the expres-
sion  of  PI3K  in  DN-EC  thyrocytes  could  be
involved in the cascade of immune events, such
as in presenting antigens and recalling up lym-
phocytes. 
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